Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

COGT

Cogent Biosciences (COGT)

Cogent Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COGT
DateTimeSourceHeadlineSymbolCompany
01/08/20257:00AMGlobeNewswire Inc.Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:COGTCogent Biosciences Inc
12/09/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
12/09/20246:00AMGlobeNewswire Inc.Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsNASDAQ:COGTCogent Biosciences Inc
12/08/202411:00AMGlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)NASDAQ:COGTCogent Biosciences Inc
11/14/20243:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:COGTCogent Biosciences Inc
11/14/202411:24AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:COGTCogent Biosciences Inc
11/12/20247:00AMGlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
11/05/20248:00AMGlobeNewswire Inc.Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) MeetingNASDAQ:COGTCogent Biosciences Inc
10/23/20246:00AMGlobeNewswire Inc.Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:COGTCogent Biosciences Inc
09/03/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
09/03/20247:00AMGlobeNewswire Inc.Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility AnalysisNASDAQ:COGTCogent Biosciences Inc
08/06/20243:53PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:COGTCogent Biosciences Inc
08/06/20247:40AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
08/06/20247:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
08/06/20247:00AMGlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
06/27/20247:00AMGlobeNewswire Inc.Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trialNASDAQ:COGTCogent Biosciences Inc
06/14/20246:30AMGlobeNewswire Inc.Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)NASDAQ:COGTCogent Biosciences Inc
06/13/20246:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
06/13/20246:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
06/13/20246:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
06/13/20246:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
06/13/20245:06AMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
06/12/20248:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
06/05/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
05/29/20243:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
05/29/20243:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
05/23/20244:05PMGlobeNewswire Inc.Cogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerNASDAQ:COGTCogent Biosciences Inc
05/23/20244:01PMGlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual MeetingNASDAQ:COGTCogent Biosciences Inc
05/07/20247:26AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
05/07/20247:19AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:COGT

Your Recent History

Delayed Upgrade Clock